AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study

Inflammatory Bowel Diseases

Volumn 20, Issue 5, 2014, Pages 872-881

  Reinisch, Walter ^a   Travis, Simon ^b   Hanauer, Stephen ^c   Wang, Hong ^d   Shara, Nawar ^d,e   Harris, M Scott ^e,f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

AST 120; Crohn's disease; Fistula; Perianal disease; Spherical carbon adsorbent

Indexed keywords

ANTIBIOTIC AGENT; AST 120; AZATHIOPRINE; C REACTIVE PROTEIN; DIPHENOXYLATE; LOPERAMIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE; CARBON; GASTROINTESTINAL AGENT; MICROSPHERE; OXIDE;

ABDOMINAL PAIN; ADULT; AGED; ANUS FISTULA; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; ILEOSTOMY; INCIDENCE; INTESTINE MOTILITY; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIANAL ABSCESS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SHORT BOWEL SYNDROME; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; RECTAL FISTULA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARBON; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; OXIDES; PROSPECTIVE STUDIES; RECTAL FISTULA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902150733     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000031     Document Type: Article

References (25)

1. Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn's disease: a 35 year follow-up study of 507 patients. Gastroenterology. 1998;114:1151-1160.
2. Schwartz DA, Loftus EV, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmstead County, Minnesota. Gastroenterology. 2002;122:875-880.
3. Schwarz DA, Maltz BE. Treatment of fistulizing inflammatory bowel disease. Med Clin N Am. 2010;94:19-34.
4. Bressler B, Sands BE. Review article: medical therapy for fistulizing Crohn's disease. Aliment Pharmacol Ther. 2006;24:1283-1293.
5. Schwarz DA, Herdman CR. Review article: the medical treatment of Crohn's perianal fistulas. Aliment Pharmacol Ther. 2004;19:953-967.
6. Thia KT, Mahadevan U, Feagan BG, et al. Criprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. In flamm Bowel Dis. 2009;15:17-24.
7. West RL, van de Woude CJ, Hansen BE, et al. Clinical and endoscopic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329-1336.
8. Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther. 2003;18:1113-1120.
9. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
10. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009;58: 940-948.
11. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340: 1398-1405.
12. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
13. Owada A, Nakao M, Koike J, et al. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl. 1997;52:S188-S190.
14. Niwa T, Yazawa T, Ise M, et al. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl. 1997;52:S23-S28.
15. Yamagishi S, Nakamura K, Matsui T, et al. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end-product (AGE)-related disorders. Med Hypotheses. 2007; 69:666-668.
16. Shen B, Pardi D, Bennett A, et al. The efficacy and tolerability of AST- 120 (spherical carbon adsorbent) in active pouchitis. Am J Gastroenterol. 2009;104:1468-1474.
17. Fukuda Y, Takazoe M, Sugita A, et al. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2008;103:1721-1729.
18. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity Index. Gastroenterology. 1976;70:439-444.
19. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index: McMaster IBD Study Group. J Clin Gastroenterol. 1995;20:27-32.
20. Hirakawa H, Fukuda Y, Tanida N, et al. Home elemental enteral hyperalimentation (HEEH) for the maintenance of remission in patients with Crohn's disease. Gastroenterol Jpn. 1993;28:379-384.
21. Sandborn WJ, Present DH, Isaacs KI, et al. Tacrolimus for the treatment of tistulas in patients with Crohn's disease: a randomized, placebocontrolled trial. Gastroenterology. 2003;125:380-388.
22. Schreiber S, Lawrance IC, Thomsen OØ, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease-subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011;33:185-193.
23. Tozer PJ, Whelan K, Phillips KS, et al. Etiology of perianal Crohn's disease: role of genetic, microbiological, and immunological factors. In flamm Bowel Dis. 2009;15:1591-1598.
24. Araki Y, Tsujikawa T, Andoh A, et al. Therapeutic effects of an oral adsorbent on acute dextran sulphate sodium induced colitis and its recovery phase in rats, especially effects of elimination of bile acids in gut lumen. Dig Liver Dis. 2000;32:691-698.
25. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.